The startup develops orthopedic regenerative medicine products utilizing stem cell technology and advanced biomaterials to enhance long-term tissue regeneration. Their solutions aim to improve healing times and reduce pain for patients with orthopedic injuries.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for repairing damaged or diseased bone and tissue often result in incomplete regeneration, leading to prolonged recovery times and suboptimal patient outcomes. Traditional treatments may also require high doses of biologics, increasing the risk of non-specific effects and complications.
Solution
Renovos offers RENOVITE, a synthetic nanoclay platform that enhances tissue regeneration through precise and localized delivery of therapeutics. The injectable nanoclay gel acts as a scaffold, attracting regenerative cells and templating new tissue formation. RENOVITE retains delivered biologics at the target site, enabling the use of ultra-low effective doses for safer and more efficient tissue regeneration. As new tissue forms, the nanoclay is gradually resorbed, leaving behind only regenerated tissue.
Target Audience
The primary target audience includes orthopedic surgeons, spine surgeons, and other medical professionals focused on regenerative medicine and tissue repair.
Features
- Synthetic nanoclay gel (RENOVITE) for localized therapeutic delivery
- Injectable formulation suitable for minimally invasive procedures, delivered via a 23G needle
- High-precision handling for targeted placement and retention of biologics
- Enhanced bone fusion quality, avoiding the "eggshell effect"
- Customizable for delivery of a broad variety of molecules, including BMP-2
- Biocompatible and resorbable material gradually replaced by newly regenerated tissue
- Reduced risk of non-specific effects due to localized delivery